scPharmaceuticals Inc
NASDAQ:SCPH
scPharmaceuticals Inc
Research & Development
scPharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
scPharmaceuticals Inc
NASDAQ:SCPH
|
Research & Development
-$15.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
scPharmaceuticals Inc
Glance View
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2017-11-17. The firm is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The firm's wholly owned subsidiary is scPharmaceuticals Securities Corporation.
See Also
What is scPharmaceuticals Inc's Research & Development?
Research & Development
-15.4m
USD
Based on the financial report for Jun 30, 2025, scPharmaceuticals Inc's Research & Development amounts to -15.4m USD.
What is scPharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 5Y
7%
Over the last year, the Research & Development growth was -27%. The average annual Research & Development growth rates for scPharmaceuticals Inc have been 5% over the past three years , 7% over the past five years .
